

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Recent advances in the search for a targeted... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/8-1532/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/8-1532" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Recent advances in the search for a targeted immunomodulatory therapy for primary Sjögren’s syndrome" />
    
            <meta name="og:title" content="F1000Research Article: Recent advances in the search for a targeted immunomodulatory therapy for primary Sj&amp;ouml;gren&rsquo;s syndrome.">
            <meta name="og:description" content="Read the latest article version by David L. Leverenz, E. William St. Clair, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="21770">
            <meta name="article-id" content="19842">
            <meta name="dc.title" content="Recent advances in the search for a targeted immunomodulatory therapy for primary Sj&amp;ouml;gren&rsquo;s syndrome">
            <meta name="dc.description" content="Primary Sj&amp;ouml;gren&rsquo;s syndrome is a chronic autoimmune disease characterized by salivary and lacrimal gland dysfunction, leading to substantial morbidity and reduced quality of life. Many patients with primary Sj&amp;ouml;gren&rsquo;s syndrome also have extraglandular systemic complications, some of which can be organ- or life-threatening. Over the last decade, numerous targeted immunomodulatory therapies for primary Sj&amp;ouml;gren&rsquo;s syndrome have failed to show a benefit in clinical trials, and as yet no disease-modifying therapy has been approved for this disease. Herein, we provide an updated review of the clinical trial landscape for primary Sj&amp;ouml;gren&rsquo;s syndrome and the numerous efforts to move the field forward, including the development of new classification criteria and outcome measures, the results of recent clinical trials in this field, the challenges faced in the search for effective therapies, and the expanding pipeline of novel therapies under development.">
            <meta name="dc.subject" content="Sj&ouml;gren's Syndrome, Sicca, Rheumatologic diseases">
            <meta name="dc.creator" content="Leverenz, David L.">
            <meta name="dc.creator" content="St. Clair, E. William">
            <meta name="dc.date" content="2019/08/29">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.19842.1">
            <meta name="dc.source" content="F1000Research 2019 8:1532">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="Sj&ouml;gren's Syndrome">
            <meta name="prism.keyword" content="Sicca">
            <meta name="prism.keyword" content="Rheumatologic diseases">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2019/08/29">
            <meta name="prism.volume" content="8">
            <meta name="prism.number" content="1532">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.19842.1">
            <meta name="prism.url" content="https://f1000research.com/articles/8-1532">
            <meta name="citation_title" content="Recent advances in the search for a targeted immunomodulatory therapy for primary Sj&amp;ouml;gren&rsquo;s syndrome">
            <meta name="citation_abstract" content="Primary Sj&amp;ouml;gren&rsquo;s syndrome is a chronic autoimmune disease characterized by salivary and lacrimal gland dysfunction, leading to substantial morbidity and reduced quality of life. Many patients with primary Sj&amp;ouml;gren&rsquo;s syndrome also have extraglandular systemic complications, some of which can be organ- or life-threatening. Over the last decade, numerous targeted immunomodulatory therapies for primary Sj&amp;ouml;gren&rsquo;s syndrome have failed to show a benefit in clinical trials, and as yet no disease-modifying therapy has been approved for this disease. Herein, we provide an updated review of the clinical trial landscape for primary Sj&amp;ouml;gren&rsquo;s syndrome and the numerous efforts to move the field forward, including the development of new classification criteria and outcome measures, the results of recent clinical trials in this field, the challenges faced in the search for effective therapies, and the expanding pipeline of novel therapies under development.">
            <meta name="citation_description" content="Primary Sj&amp;ouml;gren&rsquo;s syndrome is a chronic autoimmune disease characterized by salivary and lacrimal gland dysfunction, leading to substantial morbidity and reduced quality of life. Many patients with primary Sj&amp;ouml;gren&rsquo;s syndrome also have extraglandular systemic complications, some of which can be organ- or life-threatening. Over the last decade, numerous targeted immunomodulatory therapies for primary Sj&amp;ouml;gren&rsquo;s syndrome have failed to show a benefit in clinical trials, and as yet no disease-modifying therapy has been approved for this disease. Herein, we provide an updated review of the clinical trial landscape for primary Sj&amp;ouml;gren&rsquo;s syndrome and the numerous efforts to move the field forward, including the development of new classification criteria and outcome measures, the results of recent clinical trials in this field, the challenges faced in the search for effective therapies, and the expanding pipeline of novel therapies under development.">
            <meta name="citation_keywords" content="Sj&ouml;gren's Syndrome, Sicca, Rheumatologic diseases">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="David L. Leverenz">
            <meta name="citation_author_institution" content="Department of Medicine, Division of Rheumatology and Immunology, School of Medicine, Duke University, 40 Duke Medicine Circle, Durham, NC, 27110, USA">
            <meta name="citation_author" content="E. William St. Clair">
            <meta name="citation_author_institution" content="Department of Medicine, Division of Rheumatology and Immunology, School of Medicine, Duke University, 40 Duke Medicine Circle, Durham, NC, 27110, USA">
            <meta name="citation_publication_date" content="2019/08/29">
            <meta name="citation_volume" content="8">
            <meta name="citation_publication_number" content="1532">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.19842.1">
            <meta name="citation_firstpage" content="1532">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/8-1532/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/8-1532.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=21770 /> <input type=hidden id=articleId name=articleId value=19842 /> <input type=hidden id=xmlUrl value="/articles/8-1532/v1/xml"/> <input type=hidden id=xmlFileName value="-8-1532-v1.xml"> <input type=hidden id=article_uuid value=9c7745fc-6f25-43ef-828b-474d9001c418 /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Recent advances in the search for a targeted immunomodulatory therapy for primary Sj&ouml;gren’s syndrome"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.19842.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.19842.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/8-1532"
  },
  "headline": "Recent advances in the search for a targeted immunomodulatory therapy for primary Sjögren’s...",
  "datePublished": "2019-08-29T13:46:06",
  "dateModified": "2019-08-29T13:46:06",
  "author": [
    {
      "@type": "Person",
      "name": "David L. Leverenz"
    },    {
      "@type": "Person",
      "name": "E. William St. Clair"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Primary Sj&amp;ouml;gren&rsquo;s syndrome is a chronic autoimmune disease characterized by salivary and lacrimal gland dysfunction, leading to substantial morbidity and reduced quality of life. Many patients with primary Sj&amp;ouml;gren&rsquo;s syndrome also have extraglandular systemic complications, some of which can be organ- or life-threatening. Over the last decade, numerous targeted immunomodulatory therapies for primary Sj&amp;ouml;gren&rsquo;s syndrome have failed to show a benefit in clinical trials, and as yet no disease-modifying therapy has been approved for this disease. Herein, we provide an updated review of the clinical trial landscape for primary Sj&amp;ouml;gren&rsquo;s syndrome and the numerous efforts to move the field forward, including the development of new classification criteria and outcome measures, the results of recent clinical trials in this field, the challenges faced in the search for effective therapies, and the expanding pipeline of novel therapies under development."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/8-1532/v1",
            "name": "Recent advances in the search for a targeted immunomodulatory therapy..."
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Recent advances in the search for a targeted immunomodulatory therapy... </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=21770 data-id=19842 data-downloads="" data-views="" data-scholar="10.12688/f1000research.19842.1" data-recommended="" data-doi="10.12688/f1000research.19842.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/8-1532/v1/pdf?article_uuid=9c7745fc-6f25-43ef-828b-474d9001c418" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-19842-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-19842-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-19842-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Leverenz DL and St. Clair EW. Recent advances in the search for a targeted immunomodulatory therapy for primary Sj&ouml;gren’s syndrome [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):1532 (<a class=new-orange href="https://doi.org/10.12688/f1000research.19842.1" target=_blank>https://doi.org/10.12688/f1000research.19842.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-19842-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=19842 id=track-article-signin-19842 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/19842?target=/articles/8-1532/v1">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=21770 /> <input name=articleId type=hidden value=19842 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Recent advances in the search for a targeted immunomodulatory therapy for primary Sj&ouml;gren’s syndrome</h1><span class=other-info> [version 1; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class="">David L. Leverenz<a href="https://orcid.org/0000-0002-2415-0690" target=_blank id=author-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-2415-0690</div>,&nbsp;</span><span class=""><a href="mailto:eugene.st.clair@duke.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>E. William St. Clair</span></a></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class="">David L. Leverenz<a href="http://orcid.org/0000-0002-2415-0690" target=_blank id=mauthor-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-2415-0690</div>,&nbsp;</span><span class=""><a href="mailto:eugene.st.clair@duke.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>E. William St. Clair</span></a></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 29 Aug 2019 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.19842.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Department of Medicine, Division of Rheumatology and Immunology, School of Medicine, Duke University, 40 Duke Medicine Circle, Durham, NC, 27110, USA<br/> <p> <div class=margin-bottom> David L. Leverenz <br/> <span>Roles: </span> Conceptualization, Data Curation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> E. William St. Clair <br/> <span>Roles: </span> Conceptualization, Data Curation, Project Administration, Supervision, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=55980-52887></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=55979-52888></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Primary Sj&ouml;gren’s syndrome is a chronic autoimmune disease characterized by salivary and lacrimal gland dysfunction, leading to substantial morbidity and reduced quality of life. Many patients with primary Sj&ouml;gren’s syndrome also have extraglandular systemic complications, some of which can be organ- or life-threatening. Over the last decade, numerous targeted immunomodulatory therapies for primary Sj&ouml;gren’s syndrome have failed to show a benefit in clinical trials, and as yet no disease-modifying therapy has been approved for this disease. Herein, we provide an updated review of the clinical trial landscape for primary Sj&ouml;gren’s syndrome and the numerous efforts to move the field forward, including the development of new classification criteria and outcome measures, the results of recent clinical trials in this field, the challenges faced in the search for effective therapies, and the expanding pipeline of novel therapies under development. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> Sjögren's Syndrome, Sicca, Rheumatologic diseases </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> E. William St. Clair (<a href="mailto:eugene.st.clair@duke.edu">eugene.st.clair@duke.edu</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> E. William St. Clair </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> DLL declares that he has no competing interests. EWS has been a consultant for and received a research grant from Bristol-Myers Squibb and has been a consultant for Viela Bio and Abbvie. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The author(s) declared that no grants were involved in supporting this work. </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2019 Leverenz DL and St. Clair EW. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Leverenz DL and St. Clair EW. Recent advances in the search for a targeted immunomodulatory therapy for primary Sj&ouml;gren’s syndrome [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):1532 (<a href="https://doi.org/10.12688/f1000research.19842.1" target=_blank>https://doi.org/10.12688/f1000research.19842.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 29 Aug 2019, <b>8</b>(F1000 Faculty Rev):1532 (<a href="https://doi.org/10.12688/f1000research.19842.1" target=_blank>https://doi.org/10.12688/f1000research.19842.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 29 Aug 2019, <b>8</b>(F1000 Faculty Rev):1532 (<a href="https://doi.org/10.12688/f1000research.19842.1" target=_blank>https://doi.org/10.12688/f1000research.19842.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d11211e151>Introduction</h2><p class="" id=d11211e154>Primary Sjögren’s syndrome (pSS) is a chronic autoimmune disease characterized by salivary and lacrimal gland dysfunction, leading to substantial morbidity and reduced quality of life. Patients with pSS not only experience the consequences of exocrine gland deficiency but also may manifest systemic complications, including profound fatigue, rash, arthritis, interstitial lung disease, nephritis, and neuropathy. They also carry an increased risk for non-Hodgkin’s B-cell lymphoma. Since the description of this syndrome by Henrik Sjögren in 1933<sup><a href="#ref-1">1</a></sup>, extensive efforts have been made to classify pSS more precisely, understand its pathogenesis, and develop effective treatments. Despite these efforts, the management of pSS has not advanced much beyond alleviating symptoms of glandular dysfunction and controlling any systemic manifestations by using immunomodulatory agents borrowed from the therapeutic armamentarium of other autoimmune diseases, such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). To date, there is no proven disease-modifying therapy for pSS.</p><p class="" id=d11211e161>There are several reasons why disease-modifying therapies for Sjögren’s syndrome have struggled to reach the clinic. First, the field has been slow to embrace the development of novel targeted therapies for pSS compared with the extensive work devoted to finding novel therapies for RA and other types of inflammatory arthritis. Until recently, a prevailing view among many pharmaceutical and biotechnology companies was the misperception that pSS was a relatively benign condition and not an area ripe for investment. The outlook for developing new drugs for the treatment of pSS has changed in the last several years with the recognition that glandular dysfunction is more than a nuisance and that extraglandular disease may be fraught with serious complications. Second, the development of disease-modifying therapies for pSS has been more challenging than was expected when compared with the relative success in finding new therapies for RA and other systemic inflammatory diseases. The results of two randomized, placebo-controlled trials showing that rituximab lacks clinical efficacy in pSS have been sobering for the field.</p><p class="" id=d11211e164>The failure of rituximab and many other immunomodulatory therapies for pSS has illuminated a number of challenges in the design of clinical trials for pSS, in particular regarding patient selection, assessment of treatment efficacy, and the identification of viable therapeutic targets (<a href="#T1">Table 1</a>). What is the appropriate strategy for selecting the study population in clinical trials? To this end, the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) recently revised the classification criteria for Sjögren’s syndrome. However, this scheme, like previous criteria, tends to capture a clinically heterogeneous group of patients in varying stages of disease. It is also uncertain how to identify patients with reversible glandular dysfunction, which is important for testing a new drug with potential efficacy for improving tear and salivary flow. To increase the likelihood of detecting an improvement in glandular function, many clinical trials of late have required eligible subjects to show residual stimulated whole salivary flow.</p><a name=T1 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 1. Current challenges in clinical trials of new therapies for primary Sjögren’s syndrome.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d11211e181 class=n-a></a><tbody><a name=d11211e183 class=n-a></a><tr><a name=d11211e185 class=n-a></a><td colspan=1 rowspan=1><a name=d11211e187 class=n-a></a><b>Selection of study population</b><br class=br>&nbsp;&nbsp;&nbsp;&nbsp;•&nbsp;&nbsp;&nbsp;Identifying patients with reversible glandular dysfunction<br class=br>&nbsp;&nbsp;&nbsp;&nbsp;•&nbsp;&nbsp;&nbsp;Individuals with diverse extraglandular features may not respond alike to a particular therapy.<br class=br>&nbsp;&nbsp;&nbsp;&nbsp;•&nbsp;&nbsp;&nbsp;Lack of patient stratification (for example, defined on the basis of mechanism or predictive biomarker) may obscure<br class=br>detection of therapeutic response.<br class=br><b>Assessment of treatment efficacy</b><br class=br>&nbsp;&nbsp;&nbsp;&nbsp;•&nbsp;&nbsp;&nbsp;Limited sensitivity to change of patient-reported symptom scales<br class=br>&nbsp;&nbsp;&nbsp;&nbsp;•&nbsp;&nbsp;&nbsp;Drawbacks of collapsing a multi-domain index, such as the EULAR Sjögren’s syndrome Disease Activity Index (ESSDAI), into<br class=br>a single measure of disease activity for use as a primary endpoint<br class=br>&nbsp;&nbsp;&nbsp;&nbsp;•&nbsp;&nbsp;&nbsp;Lack of reliable biomarkers of disease activity to substantiate treatment efficacy<br class=br><b>Identification of therapeutic targets</b><br class=br>&nbsp;&nbsp;&nbsp;&nbsp;•&nbsp;&nbsp;&nbsp;Disease-modifying agents (including biologics) effective in other autoimmune diseases have not been effective in primary<br class=br>Sjögren’s syndrome.<br class=br>&nbsp;&nbsp;&nbsp;&nbsp;•&nbsp;&nbsp;&nbsp;Monotherapy may be inadequate to control disease activity. (For example, combinations of drugs targeting different aspects<br class=br>of the pathologic response may be required.)<br class=br>&nbsp;&nbsp;&nbsp;&nbsp;•&nbsp;&nbsp;&nbsp;More work is needed on targeting the interaction of immune cells with acinar and ductal epithelial cells to potentially reverse<br class=br>glandular dysfunction.</td></tr></tbody></table></div><p class="" id=d11211e232>The identification of effective therapies for pSS will depend on the validity, reliability, responsiveness, ceiling effects, and floor effects of the outcome measures used in the clinical trials. Recent and ongoing trials have relied mostly on the EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) and EULAR Sjögren’s Syndrome Patient-Reported Index (ESSPRI), which are validated outcome measures for the assessment of systemic activity and patient symptoms, respectively. The ESSDAI is a multi-domain index that collapses a weighted score from each of 10 different clinical items, a hematologic item, and a biological item into a single score. The ESSDAI is considered the gold standard for assessing systemic disease activity in clinical trials, and a minimum score of 5 is usually set as an eligibility requirement in clinical trials testing therapies aimed at reducing systemic disease. This approach may be problematic in a clinically heterogeneous disease such as pSS. One potential pitfall is that patients with a diverse array of organ system involvement may not have the same chance of improving their score owing to differences in the sensitivity of that domain or item’s scale to change and the inherent responsiveness of a given domain or item to therapy. In addition, changes between the pre-defined categories of absent, low, moderate, or high disease activity may underestimate or overestimate the extent of improvement, depending on the baseline assessment.</p><p class="" id=d11211e235>Another reason for the slow progress in bringing new drugs into the clinic may relate to the strategy for choosing a therapeutic target. Therapies tested thus far in pSS have been based mostly on a track record of success in SLE (for example, belimumab and rituximab) or RA (for example, rituximab and abatacept) owing to the overlap in clinical and pathologic features among these autoimmune diseases. This strategy has obvious drawbacks, as our recent experience has taught us. pSS likely has unique immune mechanisms at play, particularly in light of the important role of epithelial cells in the pathogenesis of this disease. New therapies should be considered on the basis of a strong scientific rationale relevant to the pathogenesis of pSS.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d11211e241>Clinical trials in primary Sjögren’s syndrome: coming up dry</h2><p class="" id=d11211e244>Hydroxychloroquine, which has been proven effective for the treatment of SLE and RA, has been prescribed for patients with pSS with the goal of improving symptoms of fatigue and arthritis. However, such a benefit was not confirmed in a randomized clinical trial of hydroxychloroquine therapy for pSS (Randomized Evaluation of hydroxychloroquine in primary <b>Sjögren’s</b> syndrome, known as the JOQUER trial)<sup><a href="#ref-2">2</a></sup>. Prior to that study, a number of open-label and retrospective studies had demonstrated possible benefits of hydroxychloroquine for reducing fatigue, arthralgia, myalgia, and dryness in pSS<sup><a href="#ref-3">3</a>–<a href="#ref-6">6</a></sup>. However, the JOQUER trial failed to show a significant impact of hydroxychloroquine therapy on any of these patient-reported measures. As discussed later, in pSS, indices of patient-reported symptoms are not sensitive to change over time and therefore the outcome measures used in the JOQUER trial may have underestimated the true effect of hydroxychloroquine treatment on improving fatigue and arthralgia.</p><p class="" id=d11211e261>Recently, rituximab therapy failed to show a benefit in two clinical trials despite the compelling evidence supporting the key roles of B-cells in disease pathogenesis, such as the high prevalence of autoantibodies and hypergammaglobulinemia, the presence of germinal center–like structures in salivary gland biopsies, the increased risk of non-Hodgkin’s B-cell lymphoma, and genetic studies linking the risk for pSS with polymorphisms in genes critical for B-cell development<sup><a href="#ref-7">7</a>,<a href="#ref-8">8</a></sup>. The optimism for targeting B-cells was fueled by promising results in early pilot studies of rituximab in pSS<sup><a href="#ref-9">9</a>–<a href="#ref-11">11</a></sup>. However, these results were not confirmed in the two large trials. The Tolerance and Efficacy of Rituximab in pSS (TEARS) trial evaluated the effect of rituximab therapy on the symptoms of pSS, employing as outcome measures four patient-reported visual analogue scales (VASs): global disease, pain, fatigue, and dryness<sup><a href="#ref-12">12</a></sup>. The proportions of patients with a treatment response, as defined by an improvement of 30 mm or more in two out of four VAS outcome measures, were not significantly different between the rituximab and placebo groups. There were some suggestions of clinical efficacy, as some pre-specified secondary analyses showed a significant difference between the rituximab and placebo groups at weeks 6 and 16, particularly in the fatigue domain.</p><p class="" id=d11211e282>The Trial of Anti-B cell Therapy in Patients with pSS (TRACTISS) began enrollment later and called for two courses of rituximab (or placebo) and used a primary endpoint defined as the proportion of patients achieving a 30% reduction in fatigue or oral dryness by VAS at 48 weeks<sup><a href="#ref-13">13</a></sup>. Secondary outcomes included measures of salivary and lacrimal flow. The results of this trial also showed no significant differences between rituximab and placebo for the primary endpoint or any of the secondary endpoints, except for a small improvement in unstimulated salivary flow rate in the group that received rituximab.</p><p class="" id=d11211e289>Lymphotoxin beta (LT-β) is required for the formation of lymph nodes and germinal centers and thus is an alternative approach for targeting B cell–mediated immune responses. LT-α induces the secretion of interferon and chemokines, and LT-α/LT-β heterodimers stimulate the development of ectopic germinal center–like structures<sup><a href="#ref-14">14</a></sup>. Animal models had previously shown that blocking LT-β prevents lymphoid organization in salivary glands and improves their function<sup><a href="#ref-15">15</a></sup>, and human studies had shown that LT-β is upregulated in salivary gland tissue of patients with pSS<sup><a href="#ref-16">16</a></sup>. However, in a randomized, placebo-controlled, phase II clinical trial, baminercept, an LT-β receptor fusion protein, failed to positively impact any of the clinical measures of disease activity despite evidence of a biological effect<sup><a href="#ref-17">17</a></sup>.</p><p class="" id=d11211e309>Abatacept, another biologic investigated in pSS, mimics the activity of CTLA-4 and prevents T-cell co-stimulation. It is approved for the treatment of RA and psoriatic arthritis in adults and juvenile idiopathic arthritis in children and had shown promise in open-label studies of patients with pSS<sup><a href="#ref-18">18</a>,<a href="#ref-19">19</a></sup>. The results of a randomized, placebo-controlled phase III trial of abatacept in 187 patients with pSS were reported at a scientific meeting and indicated that 24 weeks of abatacept therapy was no better than placebo for improving any of the clinical outcome measures, including the ESSDAI or ESSPRI<sup><a href="#ref-20">20</a></sup>. Ongoing trials in the Sjögren’s syndrome area investigating the agents mentioned above as well as others are listed in <a href="#T2">Table 2</a>.</p><a name=T2 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 2. Ongoing clinical trials in the ClinicalTrials.gov database evaluating targeted therapies for primary Sjögren’s syndrome.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d11211e337 class=n-a></a><thead><a name=d11211e339 class=n-a></a><tr><a name=d11211e341 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d11211e343 class=n-a></a>ClinicalTrials.<br class=br>gov identifier</th><th align=left colspan=1 rowspan=1 valign=top><a name=d11211e348 class=n-a></a>Molecule</th><th align=left colspan=1 rowspan=1 valign=top><a name=d11211e351 class=n-a></a>Phase</th><th align=left colspan=1 rowspan=1 valign=top><a name=d11211e354 class=n-a></a>Targeted<br class=br>number of<br class=br>subjects</th><th align=left colspan=1 rowspan=1 valign=top><a name=d11211e361 class=n-a></a>Selected eligibility criteria</th><th align=left colspan=1 rowspan=1 valign=top><a name=d11211e365 class=n-a></a>Primary endpoint</th><th align=left colspan=1 rowspan=1 valign=top><a name=d11211e368 class=n-a></a>Status</th></tr></thead><tbody><a name=d11211e373 class=n-a></a><tr><a name=d11211e375 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d11211e377 class=n-a></a>NCT02631538</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11211e380 class=n-a></a>Belimumab<br class=br>(anti-BAFF) and<br class=br>Rituximab<br class=br>(anti-CD20)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11211e389 class=n-a></a>II</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11211e392 class=n-a></a>79</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11211e395 class=n-a></a>ESSDAI ≥ 5<br class=br>Baseline unstimulated salivary flow<br class=br>&gt; 0 mL/min or stimulated salivary<br class=br>flow &gt; 0.05 mL/min</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11211e405 class=n-a></a>SAEs and AESIs</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11211e408 class=n-a></a>Active, not<br class=br>recruiting</td></tr><tr><a name=d11211e414 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d11211e416 class=n-a></a>NCT02962895</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11211e419 class=n-a></a>VAY736<br class=br>(anti-BAFF-R)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11211e424 class=n-a></a>II</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11211e427 class=n-a></a>180</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11211e430 class=n-a></a>ESSDAI ≥ 6 from seven selected<br class=br>domains</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11211e436 class=n-a></a>Unspecified<br class=br>disease<br class=br>assessment</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11211e443 class=n-a></a>Recruiting</td></tr><tr><a name=d11211e447 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d11211e449 class=n-a></a>NCT03627065</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11211e452 class=n-a></a>Paraclisib<br class=br>(PI3Kδ inhibitor)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11211e457 class=n-a></a>II</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11211e460 class=n-a></a>12</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11211e463 class=n-a></a>ESSDAI ≥ 5<br class=br>SGUS ≥ 2</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11211e469 class=n-a></a>SGUS</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11211e472 class=n-a></a>Recruiting</td></tr><tr><a name=d11211e476 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d11211e478 class=n-a></a>NCT02067910</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11211e481 class=n-a></a>Abatacept<br class=br>(CTLA4 Ig)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11211e486 class=n-a></a>III</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11211e489 class=n-a></a>80</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11211e492 class=n-a></a>ESSDAI ≥ 5<br class=br>+ parotid gland biopsy</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11211e498 class=n-a></a>ESSDAI</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11211e501 class=n-a></a>Active, not<br class=br>recruiting</td></tr><tr><a name=d11211e507 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d11211e509 class=n-a></a>NCT02915159</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11211e512 class=n-a></a>Abatacept<br class=br>(CTLA4 Ig)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11211e517 class=n-a></a>III</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11211e520 class=n-a></a>253</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11211e523 class=n-a></a>ESSDAI ≥ 5</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11211e527 class=n-a></a>ESSDAI</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11211e530 class=n-a></a>Active, not<br class=br>recruiting<sup><a href="#TFN1">a</a></sup>,<sup><a href="#ref-20">20</a></sup></td></tr><tr><a name=d11211e544 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d11211e546 class=n-a></a>NCT03905525</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11211e549 class=n-a></a>CFZ533<br class=br>(anti-CD40)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11211e554 class=n-a></a>II</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11211e557 class=n-a></a>260</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11211e560 class=n-a></a>Stimulated whole salivary flow<br class=br>≥ 1 mL/min AND<br class=br>ESSDAI ≥ 5 from eight selected<br class=br>domains OR ESSPRI fatigue or<br class=br>dryness sub-scores ≥ 5</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11211e572 class=n-a></a>ESSDAI and ESSPRI</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11211e575 class=n-a></a>Not yet recruiting</td></tr><tr><a name=d11211e579 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d11211e581 class=n-a></a>NCT03100942</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11211e584 class=n-a></a>Filgotinib (JAK1)<br class=br>Lanraplenib (Syk)<br class=br>Tirabrutinib (BTK)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11211e591 class=n-a></a>II</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11211e594 class=n-a></a>152</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11211e597 class=n-a></a>ESSDAI ≥ 5</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11211e601 class=n-a></a>Protocol-specified<br class=br>response criteria</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11211e606 class=n-a></a>Active, not<br class=br>recruiting</td></tr><tr><a name=d11211e611 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d11211e613 class=n-a></a>NCT01988506</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11211e616 class=n-a></a>Low-dose IL-2 (to<br class=br>induce Treg cells)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11211e621 class=n-a></a>II</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11211e624 class=n-a></a>132<sup><a href="#TFN2">b</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d11211e630 class=n-a></a>Not reported</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11211e634 class=n-a></a>% Treg cells in<br class=br>blood</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11211e639 class=n-a></a>Recruiting</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d11211e647 class=n-a></a><p id=d11211e649> Accurate as of June 20, 2019. Excluded trials are listed as unknown, completed, withdrawn, or terminated. Also excluded are trials without an update in the ClinicalTrials.gov database in the last two years.</p><p id=TFN1><sup>a</sup>Preliminary results from this study were reported in abstract form at the European League Against Rheumatism (EULAR) national meeting in 2019 and discussed in the text of this article<sup><a href="#ref-20">20</a></sup>.</p><p id=TFN2><sup>b</sup>Trial also includes 13 other autoimmune diseases.</p><p id=d11211e666>AESI, adverse event of special interest; BAFF, B-cell activating factor; BAFF-R, B-cell activating factor receptor; BTK, Bruton’s tyrosine kinase; CTLA-4, cytotoxic T-lymphocyte associated protein-4; ESSDAI, EULAR Sjögren’s Syndrome Patient Disease Activity Index; ESSPRI, EULAR Sjögren’s Syndrome Patient-Reported Index; IL-2, interleukin 2; JAK, Janus kinase; PI3Kδ, phosphatidylinositol-3 kinase delta; SAE, serious adverse event; SGUS, salivary gland ultrasound score; Treg, regulatory T.</p></div></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d11211e675>Selection of patients for clinical trials</h2><p class="" id=d11211e678>In a clinical trial, the likelihood of detecting a treatment response depends in part on the characteristics of the study population. First, it is important to enroll patients with the disease of interest, avoiding the selection of patients with a similar set of symptoms resulting from a different disease process. The identification of eligible patients ideally should be relatively straightforward without reliance on specialized testing. The latest set of classification criteria for Sjögren’s syndrome are endorsed by both the ACR and EULAR<sup><a href="#ref-21">21</a>,<a href="#ref-22">22</a></sup>. The 2002 American-European Consensus Group (AECG)<sup><a href="#ref-23">23</a></sup> and the 2012 Sjögren’s International Collaborative Clinical Alliance Cohort (SICCAC)<sup><a href="#ref-24">24</a></sup> criteria preceded this most recent scheme. Both the 2002 AECG and 2012 SICCAC criteria depended on objective measures of dryness, autoantibody testing, and histopathology for a patient to be classified as having pSS. Although these two classification criteria had sensitivities and specificities greater than 90% for the classification of pSS, they each had issues<sup><a href="#ref-25">25</a>,<a href="#ref-26">26</a></sup>. For example, the 2002 AECG criteria relied on tests of salivary gland function unavailable in most clinics, and the 2012 SICCAC criteria were felt to be too invasive because of the requirement for corneal staining or a lip biopsy.</p><p class="" id=d11211e703>These concerns led to the development of the 2016 ACR/EULAR criteria, which are meant to be applied to patients with signs or symptoms suggestive of Sjögren’s syndrome. <a href="#T3">Table 3</a> compares the specific elements of these various classification schemes. Similar to the 2002 AECG and 2012 SICCAC criteria, the 2016 ACR/EULAR criteria rely primarily on objective tests for the classification of Sjögren’s syndrome. However, the new system differs from its predecessors by using a weighted score of each element, updating the ocular staining score domain to a more specific threshold, and eliminating anti-La/SS-B antibodies from the criteria.</p><a name=T3 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 3. Comparison of the 2002 AECG, 2012 SICCAC, and 2016 ACR/EULAR classification criteria for primary Sjögren’s syndrome.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d11211e720 class=n-a></a><thead><a name=d11211e722 class=n-a></a><tr><a name=d11211e724 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d11211e726 class=n-a></a></th><th align=left colspan=1 rowspan=1 valign=top><a name=d11211e728 class=n-a></a>2002 AECG</th><th align=left colspan=1 rowspan=1 valign=top><a name=d11211e731 class=n-a></a>2012 SICCAC</th><th align=left colspan=1 rowspan=1 valign=top><a name=d11211e734 class=n-a></a>2016 ACR/EULAR</th></tr></thead><tbody><a name=d11211e739 class=n-a></a><tr><a name=d11211e741 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d11211e743 class=n-a></a>Criteria</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11211e746 class=n-a></a>1.&nbsp;Pathology showing focal<br class=br>lymphocytic sialadenitis with a focus<br class=br>score ≥ 1<br class=br>2.&nbsp;Positive test for anti-Ro/SS-A or anti-<br class=br>La/SS-B antibodies<br class=br>3.&nbsp;Ocular signs (Schirmer I test ≤ 5 mm<br class=br>per 5 min or Rose Bengal score<br class=br>≥ 4 by the van Bijsterveld scoring<br class=br>system)<br class=br>4.&nbsp;Objective evidence of salivary gland<br class=br>involvement by salivary scintigraphy,<br class=br>parotid sialography, or unstimulated<br class=br>salivary flow rate ≤ 0.1 mL/min<br class=br>5.&nbsp;Ocular symptoms<br class=br>6.&nbsp;Oral symptoms</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11211e779 class=n-a></a>1.&nbsp;Pathology showing focal<br class=br>lymphocytic sialadenitis with a<br class=br>focus score ≥ 1<br class=br>2.&nbsp;Positive anti-Ro/SS-A OR anti-<br class=br>La/SS-B antibodies OR a positive<br class=br>test for rheumatoid factor and<br class=br>antinuclear antibodies ≥ 1:320<br class=br>3.&nbsp;Ocular staining score ≥ 3</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11211e797 class=n-a></a>1.&nbsp;Pathology showing focal<br class=br>lymphocytic sialadenitis with a<br class=br>focus score ≥ 1 (worth 3 points)<br class=br>2.&nbsp;Positive anti-Ro/SS-A antibodies<br class=br>(worth 3 points)<br class=br>3.&nbsp;SICCA ocular staining score ≥ 5 or<br class=br>Rose Bengal score ≥ 4 by the van<br class=br>Bijsterveld scoring system (worth<br class=br>1 point)<br class=br>4.&nbsp;Schirmer I test ≤ 5 mm per 5 min<br class=br>(worth 1 point)<br class=br>5.&nbsp;Unstimulated whole salivary flow<br class=br>less than 0 ≤ 0.1 mL/min (worth 1<br class=br>point)</td></tr><tr><a name=d11211e829 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d11211e831 class=n-a></a>Rules for<br class=br>classification as<br class=br>pSS</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11211e838 class=n-a></a>Patients must have at least four of the<br class=br>above six criteria provided that:<br class=br>1.&nbsp;Item 1 (pathology) is positive OR<br class=br>2.&nbsp;Item 2 (serology) is positive OR<br class=br>3.&nbsp;Any three of the four objective items<br class=br>(1–4) are positive </td><td align=left colspan=1 rowspan=1 valign=top><a name=d11211e851 class=n-a></a>Patients must have at least two of<br class=br>the above three criteria.</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11211e856 class=n-a></a>Patients must have a total score ≥ 4<br class=br>when the weights from the five criteria<br class=br>items above are summed AND<br class=br>1.&nbsp;At least one symptom of ocular/oral<br class=br>dryness OR<br class=br>2.&nbsp;An extraglandular manifestation of<br class=br>pSS as defined by the ESSDAI</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=fn5 class=n-a></a><p id=d11211e879> ACR, American College of Rheumatology; AECG, American-European Consensus Group; ESSDAI, EULAR Sjögren’s syndrome Disease Activity Index; EULAR, European League Against Rheumatism; pSS, primary Sjögren’s syndrome; SICCA, Sjögren’s International Collaborative Clinical Alliance; SICCAC, Sjögren’s International Collaborative Clinical Alliance Cohort.</p></div></div></div><p class="" id=d11211e885>The removal of anti-La/SS-B antibodies from the criteria is based on recent evidence that anti-La/SS-B antibodies alone are not useful for classification purposes. In a study published in 2015, Baer <i>et al</i>. analyzed the autoantibody profile of over 3,000 participants in the Sjögren’s International Collaborative Clinical Alliance (SICCA) registry and found that only 2% of patients were positive for anti-La/SS-B without the presence of concomitant anti-Ro/SS-A antibodies and that no difference in the clinical phenotype was evident between these patients who were positive for anti-La/SS-B antibody alone and patients testing negative for both anti-Ro/SS-A and anti-La/SS-B antibodies<sup><a href="#ref-27">27</a></sup>. In other words, the presence of anti-La antibodies alone lacked specificity for the diagnosis of pSS.</p><p class="" id=d11211e896>There is a high concordance between the previously published classification criteria and the 2016 ACR/EULAR criteria<sup><a href="#ref-28">28</a>–<a href="#ref-30">30</a></sup>. However, an important change from older criteria is that the latest criteria give credit for the presence of an extraglandular manifestation. For example, a patient with reduced tear flow by Schirmer’s testing, normal salivary flow, a small fiber neuropathy, and positive anti-Ro/SS-A antibodies would not have met previously published criteria. According to the 2016 ACR/EULAR criteria, however, the strong weighting of a positive test for anti-Ro/SS-A antibody and the presence of an extraglandular manifestation meets the threshold for classification as pSS. Similarly, a patient with reduced tear flow by Schirmer’s testing and a small fiber neuropathy would meet these new classification criteria if they had a positive labial salivary gland biopsy, even in the absence of anti-Ro/SS-A antibodies. This fine-tuning of the classification criteria allows patients with a predominant extraglandular feature of pSS to be included in clinical trials.</p><p class="" id=d11211e906>Whether these criteria may efficiently identify patients with early disease remains a question. Antibodies to salivary protein 1 (SP1), carbonic anhydrase 6 (CA6), and parotid secretory protein (PSP), which have been touted as early biomarkers of pSS, are reported to be present in about half the patients with this disease, including many patients negative for anti-Ro/SSA and anti-La/SS-B<sup><a href="#ref-31">31</a>,<a href="#ref-32">32</a></sup>. However, the clinical significance of these antibodies remains uncertain, as demonstrated in a study by Karakus <i>et al</i>., who compared the autoantibody profile among three groups: 46 patients with pSS, 14 patients with dry eyes but without pSS (non-SS dry eye), and 25 controls<sup><a href="#ref-33">33</a></sup>. While 61% of the patients with pSS had at least one positive test for anti-SP1, CA6, or PSP antibodies, so did 50% of the non-SS dry eye patients and 16% of controls. At this stage, the definition of “early Sjögren’s syndrome” remains elusive and its elucidation will require large cohort studies with adequately long follow-up.</p><p class="" id=d11211e923>Salivary gland ultrasound has emerged as an intriguing diagnostic tool in the evaluation of patients with pSS. It has, an estimated sensitivity and specificity ranging from 45.8% to 91.6% and from 73% to 98.1%, respectively<sup><a href="#ref-34">34</a></sup>. In 2016, Le Goff <i>et al</i>. reported that ultrasound imaging of the parotid glands might improve the sensitivity of the 2016 ACR/EULAR classification criteria<sup><a href="#ref-29">29</a></sup>. This study assessed 290 patients with possible pSS and found that 125 (43%) met ACR/EULAR criteria. However, an additional seven patients strongly suspected to have pSS by clinical assessment were found to have abnormalities by salivary gland ultrasonography. Each of these patients had either a positive anti-Ro/SS-A antibody or an abnormal salivary gland biopsy but because of a normal Schirmer’s test, normal van Bijsterveld score for ocular dryness, or normal unstimulated whole salivary flow rate did not meet the 2016 ACR/EULAR criteria. Overall, the authors found that adding salivary gland ultrasound to the ACR/EULAR criteria increased sensitivity from 87.4% to 91.1% and only slightly decreased specificity, from 95.4% to 93.8%. There may be a practical limitation of including salivary gland ultrasonography in future classification schemes unless this technology becomes more widespread.</p><p class="" id=d11211e937>An extensive body of literature developed over several decades has provided a standardized approach for identifying and quantifying focal lymphocytic sialadenitis, the defining histologic feature of pSS<sup><a href="#ref-35">35</a>–<a href="#ref-38">38</a></sup>. This histopathologic evaluation results in a focus score, in which a focus is defined as a cluster of 50 or more lymphocytes per 4 mm<sup>2</sup> of tissue, and a focus score of greater than or equal to 1 meets the histopathologic threshold for supporting the classification of pSS (<a href="#T3">Table 3</a>). In 2015, Costa <i>et al</i>. reported that the histopathologic interpretations of labial salivary gland biopsies by expert and local pathologists in the TEARS study showed poor inter-observer reliability<sup><a href="#ref-39">39</a></sup>. In particular, local pathologists did not routinely follow a standardized protocol for determining a focus score, such that the focus score was often overestimated. In response to these and other issues, the EULAR Sjögren’s syndrome Study Group recently established consensus guidelines to improve the standardization of the acquisition and interpretation of tissue histopathology for clinical trials<sup><a href="#ref-40">40</a></sup>. These guidelines clarify important points about tissue requirements, the calculation of a focus score, identification of germinal centers, and reporting standards. Importantly, these guidelines called for a change in the methodology used to count foci of sialadenitis adjacent to areas of atrophy, duct dilation, and fibrosis. Previously, these areas have not been counted as part of the focus score, because many biopsy specimens show non-specific patterns of inflammation with mixed lymphocytic and plasma cell infiltrates as a normal response to duct damage that occurs with aging and other non-autoimmune factors<sup><a href="#ref-38">38</a></sup>. According to the new EULAR recommendations, if focal lymphocytic sialadenitis consistent with pSS is found to be present elsewhere in the biopsy, these areas of inflammation near damaged ducts should now be counted as a part of the focus score in order to better quantify the degree of damage, reduce the risk of bias in the interpretation, and improve reproducibility<sup><a href="#ref-40">40</a></sup>. If the results of labial salivary gland biopsies are used for determining eligibility in clinical trials, they should be rendered by a central pathology reading core to minimize misinterpretation and inclusion of subjects without bona fide Sjögren’s syndrome.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d11211e976>Outcome measures in clinical trials</h2><p class="" id=d11211e979>A major focus of discussion about clinical trials in pSS has centered on the adequacy of outcome measures for detecting a treatment response. The primary outcome measures used in the JOQUER, TEARS, and TRACTISS trials relied on patient-reported scales of glandular dryness, pain, and fatigue. Many investigators have questioned whether the failure of these trials to find a treatment response in the active arm could be due, at least in part, to a lack of sensitivity of the outcome measures. Clinical trials in pSS have shifted almost exclusively to using the ESSDAI as the primary outcome measure because the main objective of these studies has been to determine whether the experimental treatment affects systemic disease activity (<a href="#T2">Table 2</a>). The ESSDAI, which was developed in 2010 by the EULAR Sjögren’s Syndrome Task Force, quantifies the extent of systemic disease activity in 12 different domains: constitutional, lymphadenopathy, glandular enlargement, articular, cutaneous, pulmonary, renal, muscular, peripheral nervous system, central nervous system, hematologic, and biological (hypocomplementemia, hypergammaglobulinemia, or cryoglobulinemia)<sup><a href="#ref-41">41</a></sup>. Each domain score in the ESSDAI is derived from physician-entered data and objective diagnostic testing. In a multi-center validation study of the ESSDAI, Seror <i>et al</i>. demonstrated that the ESSDAI correlated poorly with patient-reported measures (including the ESSPRI) and that the ESSDAI is significantly more sensitive to change over time<sup><a href="#ref-42">42</a></sup>. For this reason, the ESSDAI may be better at detecting changes in disease activity than patient-centered measures. However, the ESSDAI has some potential drawbacks, as mentioned earlier. Some domains (for example, arthritis and constitutional) are more commonly scored than others, and less commonly scored items such as the renal and muscular domains will be under-represented in the evaluation of outcomes. In addition, some domains are easier to accurately assess than others. For example, lung disease may be easier to follow using serial pulmonary function tests and chest computed tomography scans than tracking the progress of peripheral neurologic disease by examination and electrophysiologic testing. Furthermore, some patients may exhibit a clinically meaningful improvement in a single clinical domain of the ESSDAI without showing a change in the composite score if the score from another domain, such as the glandular item or hematologic item, worsens with relatively less clinical impact.</p><p class="" id=d11211e996>Many of the potential pitfalls of the ESSDAI and ESSPRI arise from the substantial clinical heterogeneity of pSS. Several lines of evidence suggest that this clinical heterogeneity may be driven by non-overlapping disease mechanisms. For example, in 2016, Nishikawa <i>et al</i>. identified CXCL13, TNF-R2, CD48, B-cell activating factor (BAFF), and PD-L2 as potential serum biomarkers in patients with pSS. Intriguingly, serum levels of CXCL13 correlated positively with the lymphadenopathy, glandular, and pulmonary domains of the ESSDAI, while serum levels of CXCL13, TNF-R2, and CD48 correlated positively with the biological domain of the ESSDAI; and serum levels of TNF-R2 correlated with low uptake on salivary gland scintigraphy<sup><a href="#ref-43">43</a></sup>. In 2018, Kanne <i>et al</i>. found that patients with pSS and extraglandular involvement had increased serum levels of high mobility group box chromosomal protein 1, a pro-inflammatory cytokine also associated with renal involvement in SLE<sup><a href="#ref-44">44</a></sup>. A study published in 2018 by James <i>et al</i>. correlated markers of B-cell activity with sub-components of the ESSDAI score in 533 patients in the UK PSS Registry and found that serum levels of BAFF correlated with the peripheral nervous system domain of the ESSDAI but that serum levels of β-2 microglobulin and free light chains correlated with the cutaneous, renal, and biological domains<sup><a href="#ref-45">45</a></sup>. More work is needed to determine whether serum biomarkers can be used to subset disease in a rational way or inform the assessment of treatment response.</p><p class="" id=d11211e1021>Data from the TEARS and TRACTISS trials have been used to investigate the potential utility of ultrasound as an outcome measure in pSS. Salivary gland ultrasound can identify characteristic changes in parenchymal volume, echogenicity, homogeneity, and vascularity<sup><a href="#ref-46">46</a>,<a href="#ref-47">47</a></sup>. In the TEARS trial, 28 patients underwent testing by salivary gland ultrasound at baseline and then six months after receiving rituximab (14 patients) or placebo (14 patients). There was a statistically significant improvement in the rituximab-treated compared with the placebo-treated participants in ultrasound parameters of parotid parenchyma echostructure (50% versus 7%, <i>P</i> = 0.03) and a trend toward an improvement in submandibular gland echostructure (36% versus 7%, <i>P</i> = 0.16)<sup><a href="#ref-48">48</a></sup>. In a similar study, 52 patients in the TRACTISS trial underwent salivary gland ultrasound testing at baseline and at weeks 16 and 48 after treatment with rituximab (26 patients) or placebo (26 patients). That study also found a statistically significant improvement in salivary gland ultrasound echostructural features in the patients who received rituximab compared with placebo<sup><a href="#ref-49">49</a></sup>. Although these studies in pSS suggest that rituximab therapy has a biological impact on salivary gland abnormalities by ultrasound, the relevance of these findings to disease-modification remains to be determined.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d11211e1048>Identifying mechanistically based therapeutic targets</h2><p class="" id=d11211e1051>The pathogenesis of pSS, like that of many rheumatologic diseases, involves a complex interplay between many components in the innate and adaptive immune system<sup><a href="#ref-50">50</a></sup>. At present, several cellular components and signaling molecules and pathways—including B-cells, co-stimulatory pathways, PI3Kδ, and interferon—have emerged as potential targets for therapeutic intervention.</p><p class="" id=d11211e1058>Despite the failure of rituximab therapy to show a benefit in the TEARS and TRACTISS trials, B-cells remain a focus of interest in the treatment of pSS. A host of studies has demonstrated alterations in peripheral and tissue-resident B-cell subsets, genetic and epigenetic modifications in B-cells, and B-cell microRNA expression profiles<sup><a href="#ref-8">8</a></sup>. BAFF may promote B-cell over-activation and loss of tolerance in pSS. To date, small studies testing anti-BAFF antibodies in patients with pSS have shown equivocal results<sup><a href="#ref-51">51</a>–<a href="#ref-53">53</a></sup>. Two randomized phase II trials of anti-BAFF therapies for pSS are ongoing. In one study, belimumab has been combined with rituximab (ClinicalTrials.gov identifier: NCT02631538; <a href="#T2">Table 2</a>) on the basis of the rationale that elevated BAFF following B-cell depletion results in selection of self-reactive B-cells during the reconstitution of the B-cell repertoire<sup><a href="#ref-54">54</a></sup>. Also, patients in the TEARS study with high baseline BAFF levels had a less robust response to rituximab, raising the possibility that neutralization of BAFF improves the response to rituximab therapy<sup><a href="#ref-55">55</a>,<a href="#ref-56">56</a></sup>. In another study, this same pathway was targeted in pSS with ianalumab (VAY736), a monoclonal antibody to the BAFF receptor (BAFF-R) which is expressed on the surface of B-cells. The binding of ianalumab to B-cells blocks BAFF:BAFF-R signaling and also depletes B-cells by direct antibody-dependent cytotoxicity. A small phase II study of a single dose of this agent has demonstrated safety of ianalumab in pSS and provided preliminary evidence of efficacy with a trend toward improvements in the ESSDAI, ESSPRI, and other outcome measures<sup><a href="#ref-57">57</a></sup>. A larger phase II trial of ianalumab in pSS is in progress (ClinicalTrials.gov identifier: NCT02962895; <a href="#T2">Table 2</a>).</p><p class="" id=d11211e1094>Another potential strategy for reducing B-cell activity in pSS is inhibition of PI3Kδ, an intracellular lipid kinase that plays a critical role in B-cell receptor signal transduction<sup><a href="#ref-8">8</a></sup>. A selective inhibitor of PI3Kδ, called leniolisib, was recently approved for the treatment of chronic lymphocytic leukemia and non-Hodgkin’s lymphoma. Early studies in pSS have shown upregulation of the PI3Kδ pathway in salivary gland tissue, and murine studies of PI3Kδ inhibition have suggested possible efficacy in reducing glandular invasion by lymphocytes, cytokine production, and autoantibody production<sup><a href="#ref-58">58</a></sup>. A double-blind, randomized, placebo-controlled clinical trial of leniolisib showed an acceptable safety profile but no clear signal of efficacy by ESSDAI or patient-reported measures<sup><a href="#ref-59">59</a></sup>.</p><p class="" id=d11211e1109>The type I interferon pathway represents a linkage between altered innate and adaptive immunity in pSS. Upregulation of type I interferon-stimulated genes in local tissues and systemic immune cells of patients with pSS results in an increase in BAFF signaling, autoreactive B-cell activity, and autoantibody production<sup><a href="#ref-60">60</a></sup>. Several studies have suggested that the strength of the interferon “signature” of patients with pSS might be a criterion for selecting patients most likely to respond to targeted therapies<sup><a href="#ref-61">61</a>,<a href="#ref-62">62</a></sup>. So far, direct interferon inhibitors have not yet been tried in pSS. However, Janus kinase (JAK) inhibitors are known to substantially impact the interferon pathway and thus may offer a viable therapeutic strategy in pSS. Early support for this strategy was provided by a study of the JAK inhibitor filgotinib, which has been shown to modify messenger RNA expression of interferon-related genes and the BAFF gene in human salivary gland epithelial cells and salivary gland organoid cultures<sup><a href="#ref-63">63</a></sup>. A phase II trial of filgotinib in pSS is ongoing (ClinicalTrials.gov identifier: NCT03100942; <a href="#T2">Table 2</a>)<sup><a href="#ref-54">54</a></sup>.</p><p class="" id=d11211e1135>Although abatacept therapy failed to show clinical efficacy in a recent phase III clinical trial involving patients with pSS, other avenues for inhibiting B- and T-cell co-stimulation remain viable future treatment strategies. Antigen-presenting cells like B-cells and dendritic cells receive activating co-stimulatory signals when their CD40 receptors bind to CD40 ligand on T helper cells. Intriguingly, ductal epithelial cells in patients with pSS also express CD40<sup><a href="#ref-64">64</a></sup>. A recent study by Wieczorek <i>et al</i>. demonstrated activation of the CD40 pathway in the salivary gland tissue of a murine model of pSS; inhibiting this pathway led to a reduction in sialadenitis, ectopic lymphoid structure formation, and autoantibody production<sup><a href="#ref-65">65</a></sup>. A small phase II clinical trial showed that anti-CD40 antibody in pSS improves the ESSDAI score and other disease measures<sup><a href="#ref-54">54</a></sup>. Additional clinical trials to further evaluate this therapy are in progress (ClinicalTrials.gov identifier: NCT03905525; <a href="#T2">Table 2</a>). <a href="#T2">Table 2</a> lists the ongoing phase II and III clinical trials of targeted therapies for pSS from the ClinicalTrials.gov database.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d11211e1164>Conclusion: looking for an oasis in the desert</h2><p class="" id=d11211e1167>What progress in the future is likely to facilitate the development of new therapies for pSS? Although the results of recent studies are encouraging, it seems likely that an optimal therapeutic target has not been identified for improving glandular function or significantly modifying systemic disease across multiple domains. Perhaps, targeting the CD40–CD40L pathway will provide demonstrable clinical efficacy in this setting. Others have suggested that targeting neuroendocrine pathways may be more productive for modifying tear and salivary secretion<sup><a href="#ref-66">66</a></sup>. Epithelial cells, which are hypothesized to be key drivers of glandular inflammation, demand more attention as therapeutic targets given their capacity to interact with T- and B-cells and secrete pro-inflammatory cytokines. Fine-tuning the study population to achieve a higher likelihood of treatment response represents another strategy for optimizing the detection of treatment responses. Identification of patient subsets on the basis of predictive biomarkers (for example, biomarkers associated with a higher likelihood of treatment response) or mechanism of action of the test drug (for example, subsets with strong interferon signature for an intervention targeting interferon pathways) would be the next step in evolving toward a more personalized treatment approach.</p><p class="" id=d11211e1174>Further refinements in the ESSDAI and other outcome measures may be needed to improve the ability to detect clinically meaningful changes in systemic disease activity. Should pulmonary function studies be routinely included in clinical trials to assess changes in lung function? Can better assessments of arthritis be developed to detect important changes in the activity of joint inflammation? In patients with pSS, unlike in patients with RA, swollen joints are the exception to the rule; joint counts may prove less sensitive to change compared with their responsiveness in patients with active RA. The field could develop more sensitive patient-reported outcome measures, which, for example, might leverage internet-based mobile devices for ascertainment of time-integrated data related to the burden of fatigue and joint pain. The prospects for the discovery of the first disease-modifying therapy for pSS are indeed bright with the entry of an increasing number of exciting new agents into the pipeline.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d11211e1180>Abbreviations</h2><p class="" id=d11211e1183>ACR, American College of Rheumatology; AECG, American-European Consensus Group; BAFF, B-cell activating factor; BAFF-R, B-cell activating factor receptor; CA6, carbonic anhydrase 6; ESSDAI, EULAR Sjögren’s syndrome Disease Activity Index; ESSPRI, EULAR Sjögren’s Syndrome Patient-Reported Index; EULAR, European League Against Rheumatism; JAK, Janus kinase; JOQUER, Randomized Evaluation of hydroxychloroquine in primary Sjögren’s syndrome; LT, lymphotoxin; PSP, parotid secretory protein; pSS, primary Sjögren’s syndrome; RA, rheumatoid arthritis; SICCAC, Sjögren’s International Collaborative Clinical Alliance Cohort; SLE, systemic lupus erythematosus; SP1, salivary protein 1; TEARS, Tolerance and Efficacy of Rituximab in primary Sjögren’s syndrome; TRACTISS, Trial of Anti-B cell Therapy in Patients with primary Sjögren’s syndrome; VAS, visual analogue scale</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d11211e1 class=n-a></a><h2 class=main-title id=d11445>Grant information</h2><p>The author(s) declared that no grants were involved in supporting this work.</p></div><div class=back-section><a name=d11211e1190 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d11663>References</h2><div class="section ref-list"><a name=d11211e1190 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d11211e1197 class=n-a></a>Sjögren H: Zur kenntnis der keratoconjunctivitis sicca (To the knowledge of keratoconjunctivitis sicca). <i>Acta Ophthalmol Suppl.</i> 1933; <b>2</b>: 1–151. </span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d11211e1212 class=n-a></a>Gottenberg JE, Ravaud P, Puéchal X, <i> et al.</i>: Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial. <i>JAMA.</i> 2014; <b>312</b>(3): 249–58. <a target=xrefwindow id=d11211e1223 href="http://www.ncbi.nlm.nih.gov/pubmed/25027140">PubMed Abstract </a> | <a target=xrefwindow id=d11211e1226 href="https://doi.org/10.1001/jama.2014.7682">Publisher Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d11211e1235 class=n-a></a>Fox RI, Chan E, Benton L, <i> et al.</i>: Treatment of primary Sjögren’s syndrome with hydroxychloroquine. <i>Am J Med.</i> 1988; <b>85</b>(4A): 62–7. <a target=xrefwindow id=d11211e1246 href="http://www.ncbi.nlm.nih.gov/pubmed/3177432">PubMed Abstract </a> | <a target=xrefwindow id=d11211e1249 href="https://doi.org/10.1016/0002-9343(88)90365-8">Publisher Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d11211e1258 class=n-a></a>Fox RI, Dixon R, Guarrasi V, <i> et al.</i>: Treatment of primary Sjögren’s syndrome with hydroxychloroquine: a retrospective, open-label study. <i>Lupus.</i> 2019; <b>5 Suppl 1</b>: S31–6. <a target=xrefwindow id=d11211e1269 href="http://www.ncbi.nlm.nih.gov/pubmed/8803908">PubMed Abstract </a> | <a target=xrefwindow id=d11211e1272 href="https://doi.org/10.1177/0961203396005001081">Publisher Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d11211e1281 class=n-a></a>Tishler M, Yaron I, Shirazi I, <i> et al.</i>: Hydroxychloroquine treatment for primary Sjögren’s syndrome: its effect on salivary and serum inflammatory markers. <i>Ann Rheum Dis.</i> 1999; <b>58</b>(4): 253–6. <a target=xrefwindow id=d11211e1292 href="http://www.ncbi.nlm.nih.gov/pubmed/10364906">PubMed Abstract </a> | <a target=xrefwindow id=d11211e1295 href="https://doi.org/10.1136/ard.58.4.253">Publisher Full Text </a> | <a target=xrefwindow id=d11211e1299 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1752865">Free Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d11211e1309 class=n-a></a>Kruize AA, Hené RJ, Kallenberg CG, <i> et al.</i>: Hydroxychloroquine treatment for primary Sjögren’s syndrome: a two year double blind crossover trial. <i>Ann Rheum Dis.</i> 1993; <b>52</b>(5): 360–4. <a target=xrefwindow id=d11211e1320 href="http://www.ncbi.nlm.nih.gov/pubmed/8323383">PubMed Abstract </a> | <a target=xrefwindow id=d11211e1323 href="https://doi.org/10.1136/ard.52.5.360">Publisher Full Text </a> | <a target=xrefwindow id=d11211e1327 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1005050">Free Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d11211e1336 class=n-a></a>Nocturne G, Mariette X: Advances in understanding the pathogenesis of primary Sjögren’s syndrome. <i>Nat Rev Rheumatol.</i> 2013; <b>9</b>(9): 544–56. <a target=xrefwindow id=d11211e1344 href="http://www.ncbi.nlm.nih.gov/pubmed/23857130">PubMed Abstract </a> | <a target=xrefwindow id=d11211e1347 href="https://doi.org/10.1038/nrrheum.2013.110">Publisher Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735105828"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d11211e1356 class=n-a></a>Mielle J, Tison A, Cornec D, <i> et al.</i>: B cells in Sjögren’s syndrome: from pathophysiology to therapeutic target. <i>Rheumatology (Oxford).</i> 2019; <b>18</b>: 249, pii: key332. <a target=xrefwindow id=d11211e1367 href="http://www.ncbi.nlm.nih.gov/pubmed/30770916">PubMed Abstract </a> | <a target=xrefwindow id=d11211e1370 href="https://doi.org/10.1093/rheumatology/key332">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735105828">F1000 Recommendation</a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d11211e1383 class=n-a></a>Dass S, Bowman SJ, Vital EM, <i> et al.</i>: Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. <i>Ann Rheum Dis.</i> 2008; <b>67</b>(11): 1541–4. <a target=xrefwindow id=d11211e1394 href="http://www.ncbi.nlm.nih.gov/pubmed/18276741">PubMed Abstract </a> | <a target=xrefwindow id=d11211e1397 href="https://doi.org/10.1136/ard.2007.083865">Publisher Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d11211e1406 class=n-a></a>Devauchelle-Pensec V, Pennec Y, Morvan J, <i> et al.</i>: Improvement of Sjögren’s syndrome after two infusions of rituximab (anti-CD20). <i>Arthritis Rheum.</i> 2007; <b>57</b>(2): 310–7. <a target=xrefwindow id=d11211e1417 href="http://www.ncbi.nlm.nih.gov/pubmed/17330280">PubMed Abstract </a> | <a target=xrefwindow id=d11211e1420 href="https://doi.org/10.1002/art.22536">Publisher Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d11211e1429 class=n-a></a>Pijpe J, van Imhoff GW, Spijkervet FK, <i> et al.</i>: Rituximab treatment in patients with primary Sjögren’s syndrome: an open-label phase II study. <i>Arthritis Rheum.</i> 2005; <b>52</b>(9): 2740–50. <a target=xrefwindow id=d11211e1440 href="http://www.ncbi.nlm.nih.gov/pubmed/16142737">PubMed Abstract </a> | <a target=xrefwindow id=d11211e1443 href="https://doi.org/10.1002/art.21260">Publisher Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d11211e1453 class=n-a></a>Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, <i> et al.</i>: Treatment of primary Sjögren syndrome with rituximab: a randomized trial. <i>Ann Intern Med.</i> 2014; <b>160</b>(4): 233–42. <a target=xrefwindow id=d11211e1464 href="http://www.ncbi.nlm.nih.gov/pubmed/24727841">PubMed Abstract </a> | <a target=xrefwindow id=d11211e1467 href="https://doi.org/10.7326/M13-1085">Publisher Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727407505"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d11211e1476 class=n-a></a>Bowman SJ, Everett CC, O’Dwyer JL, <i> et al.</i>: Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren’s Syndrome. <i>Arthritis Rheumatol.</i> 2017; <b>69</b>(7): 1440–50. <a target=xrefwindow id=d11211e1487 href="http://www.ncbi.nlm.nih.gov/pubmed/28296257">PubMed Abstract </a> | <a target=xrefwindow id=d11211e1490 href="https://doi.org/10.1002/art.40093">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727407505">F1000 Recommendation</a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d11211e1503 class=n-a></a>Shen L, Suresh L, Wu J, <i> et al.</i>: A role for lymphotoxin in primary Sjogren's disease. <i>J Immunol.</i> 2010; <b>185</b>(10): 6355–63. <a target=xrefwindow id=d11211e1514 href="http://www.ncbi.nlm.nih.gov/pubmed/20952683">PubMed Abstract </a> | <a target=xrefwindow id=d11211e1517 href="https://doi.org/10.4049/jimmunol.1001520">Publisher Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d11211e1526 class=n-a></a>Gatumu MK, Skarstein K, Papandile A, <i> et al.</i>: Blockade of lymphotoxin-beta receptor signaling reduces aspects of Sjögren's syndrome in salivary glands of non-obese diabetic mice. <i>Arthritis Res Ther.</i> 2009; <b>11</b>(1): R24. <a target=xrefwindow id=d11211e1537 href="http://www.ncbi.nlm.nih.gov/pubmed/19222863">PubMed Abstract </a> | <a target=xrefwindow id=d11211e1540 href="https://doi.org/10.1186/ar2617">Publisher Full Text </a> | <a target=xrefwindow id=d11211e1544 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2688257">Free Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d11211e1553 class=n-a></a>Hjelmervik TO, Petersen K, Jonassen I, <i> et al.</i>: Gene expression profiling of minor salivary glands clearly distinguishes primary Sjögren’s syndrome patients from healthy control subjects. <i>Arthritis Rheum.</i> 2005; <b>52</b>(5): 1534–44. <a target=xrefwindow id=d11211e1564 href="http://www.ncbi.nlm.nih.gov/pubmed/15880807">PubMed Abstract </a> | <a target=xrefwindow id=d11211e1567 href="https://doi.org/10.1002/art.21006">Publisher Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d11211e1576 class=n-a></a>St Clair EW, Baer AN, Wei C, <i> et al.</i>: Clinical Efficacy and Safety of Baminercept, a Lymphotoxin β Receptor Fusion Protein, in Primary Sjögren’s Syndrome: Results From a Phase II Randomized, Double-Blind, Placebo-Controlled Trial. <i>Arthritis Rheumatol.</i> 2018; <b>70</b>(9): 1470–80. <a target=xrefwindow id=d11211e1587 href="http://www.ncbi.nlm.nih.gov/pubmed/29604186">PubMed Abstract </a> | <a target=xrefwindow id=d11211e1590 href="https://doi.org/10.1002/art.40513">Publisher Full Text </a> | <a target=xrefwindow id=d11211e1594 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6115299">Free Full Text </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718255811"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d11211e1604 class=n-a></a>Meiners PM, Vissink A, Kroese FG, <i> et al.</i>: Abatacept treatment reduces disease activity in early primary Sjögren’s syndrome (open-label proof of concept ASAP study). <i>Ann Rheum Dis.</i> 2014; <b>73</b>(7): 1393–6. <a target=xrefwindow id=d11211e1615 href="http://www.ncbi.nlm.nih.gov/pubmed/24473674">PubMed Abstract </a> | <a target=xrefwindow id=d11211e1618 href="https://doi.org/10.1136/annrheumdis-2013-204653">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718255811">F1000 Recommendation</a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d11211e1631 class=n-a></a>Adler S, Körner M, Förger F, <i> et al.</i>: Evaluation of histologic, serologic, and clinical changes in response to abatacept treatment of primary Sjögren’s syndrome: a pilot study. <i>Arthritis Care Res (Hoboken).</i> 2013; <b>65</b>(11): 1862–8. <a target=xrefwindow id=d11211e1642 href="http://www.ncbi.nlm.nih.gov/pubmed/23740889">PubMed Abstract </a> | <a target=xrefwindow id=d11211e1645 href="https://doi.org/10.1002/acr.22052">Publisher Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d11211e1654 class=n-a></a>Baer A, Gottenberg JE, St. Clair EW, <i> et al.</i>: Efficacy and Safety of abatacept in active primary Sjogren’s syndrome: Results of a randomised placebo-controlled phase III trial. <i>Ann Rheum Dis.</i> 2019; <b>78</b>(supplement 2): A89, Accessed June 17, 2019. <a target=xrefwindow id=d11211e1665 href="https://doi.org/10.1136/annrheumdis-2019-eular.2090">Publisher Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726890204"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d11211e1674 class=n-a></a>Shiboski CH, Shiboski SC, Seror R, <i> et al.</i>: 2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren’s Syndrome: A Consensus and Data-Driven Methodology Involving Three International Patient Cohorts. <i>Arthritis Rheumatol.</i> 2017; <b>69</b>(1): 35–45. <a target=xrefwindow id=d11211e1685 href="http://www.ncbi.nlm.nih.gov/pubmed/27785888">PubMed Abstract </a> | <a target=xrefwindow id=d11211e1688 href="https://doi.org/10.1002/art.39859">Publisher Full Text </a> | <a target=xrefwindow id=d11211e1692 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5650478">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726890204">F1000 Recommendation</a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726901261"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d11211e1705 class=n-a></a>Shiboski CH, Shiboski SC, Seror R, <i> et al.</i>: 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren’s syndrome: A consensus and data-driven methodology involving three international patient cohorts. <i>Ann Rheum Dis.</i> 2017; <b>76</b>(1): 9–16. <a target=xrefwindow id=d11211e1716 href="http://www.ncbi.nlm.nih.gov/pubmed/27789466">PubMed Abstract </a> | <a target=xrefwindow id=d11211e1719 href="https://doi.org/10.1136/annrheumdis-2016-210571">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726901261">F1000 Recommendation</a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d11211e1732 class=n-a></a>Vitali C, Bombardieri S, Jonsson R, <i> et al.</i>: Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. <i>Ann Rheum Dis.</i> 2002; <b>61</b>(6): 554–8. <a target=xrefwindow id=d11211e1743 href="http://www.ncbi.nlm.nih.gov/pubmed/12006334">PubMed Abstract </a> | <a target=xrefwindow id=d11211e1746 href="https://doi.org/10.1136/ard.61.6.554">Publisher Full Text </a> | <a target=xrefwindow id=d11211e1750 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1754137">Free Full Text </a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d11211e1760 class=n-a></a>Shiboski SC, Shiboski CH, Criswell L, <i> et al.</i>: American College of Rheumatology classification criteria for Sjögren’s syndrome: a data-driven, expert consensus approach in the Sjögren’s International Collaborative Clinical Alliance Cohort. <i>Arthritis Care Res (Hoboken).</i> 2012; <b>64</b>(4): 475–87. <a target=xrefwindow id=d11211e1771 href="http://www.ncbi.nlm.nih.gov/pubmed/22563590">PubMed Abstract </a> | <a target=xrefwindow id=d11211e1774 href="https://doi.org/10.1002/acr.21591">Publisher Full Text </a> | <a target=xrefwindow id=d11211e1778 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3349440">Free Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d11211e1787 class=n-a></a>Rasmussen A, Ice JA, Li H, <i> et al.</i>: Comparison of the American-European Consensus Group Sjogren’s syndrome classification criteria to newly proposed American College of Rheumatology criteria in a large, carefully characterised sicca cohort. <i>Ann Rheum Dis.</i> 2014; <b>73</b>(1): 31–8. <a target=xrefwindow id=d11211e1798 href="http://www.ncbi.nlm.nih.gov/pubmed/23968620">PubMed Abstract </a> | <a target=xrefwindow id=d11211e1801 href="https://doi.org/10.1136/annrheumdis-2013-203845">Publisher Full Text </a> | <a target=xrefwindow id=d11211e1805 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3855629">Free Full Text </a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d11211e1814 class=n-a></a>Cornec D, Saraux A, Cochener B, <i> et al.</i>: Level of agreement between 2002 American-European Consensus Group and 2012 American College of Rheumatology classification criteria for Sjögren’s syndrome and reasons for discrepancies. <i>Arthritis Res Ther.</i> 2014; <b>16</b>(2): R74. <a target=xrefwindow id=d11211e1825 href="http://www.ncbi.nlm.nih.gov/pubmed/24642022">PubMed Abstract </a> | <a target=xrefwindow id=d11211e1828 href="https://doi.org/10.1186/ar4514">Publisher Full Text </a> | <a target=xrefwindow id=d11211e1832 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4060239">Free Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d11211e1841 class=n-a></a>Baer AN, McAdams DeMarco M, Shiboski SC, <i> et al.</i>: The SSB-positive/SSA-negative antibody profile is not associated with key phenotypic features of Sjögren’s syndrome. <i>Ann Rheum Dis.</i> 2015; <b>74</b>(8): 1557–61. <a target=xrefwindow id=d11211e1852 href="http://www.ncbi.nlm.nih.gov/pubmed/25735642">PubMed Abstract </a> | <a target=xrefwindow id=d11211e1855 href="https://doi.org/10.1136/annrheumdis-2014-206683">Publisher Full Text </a> | <a target=xrefwindow id=d11211e1859 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6697481">Free Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732846667"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d11211e1868 class=n-a></a>Billings M, Amin Hadavand M, Alevizos I: Comparative analysis of the 2016 ACR-EULAR and the 2002 AECG classification criteria for Sjögren’s syndrome: Findings from the NIH cohort. <i>Oral Dis.</i> 2018; <b>24</b>(1–2): 184–90. <a target=xrefwindow id=d11211e1876 href="http://www.ncbi.nlm.nih.gov/pubmed/29480635">PubMed Abstract </a> | <a target=xrefwindow id=d11211e1879 href="https://doi.org/10.1111/odi.12772">Publisher Full Text </a> | <a target=xrefwindow id=d11211e1882 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5831553">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732846667">F1000 Recommendation</a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732234843"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d11211e1895 class=n-a></a>Le Goff M, Cornec D, Jousse-Joulin S, <i> et al.</i>: Comparison of 2002 AECG and 2016 ACR/EULAR classification criteria and added value of salivary gland ultrasonography in a patient cohort with suspected primary Sjögren's syndrome. <i>Arthritis Res Ther.</i> 2017; <b>19</b>(1): 269. <a target=xrefwindow id=d11211e1906 href="http://www.ncbi.nlm.nih.gov/pubmed/29208023">PubMed Abstract </a> | <a target=xrefwindow id=d11211e1909 href="https://doi.org/10.1186/s13075-017-1475-x">Publisher Full Text </a> | <a target=xrefwindow id=d11211e1913 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5717850">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732234843">F1000 Recommendation</a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727448421"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d11211e1927 class=n-a></a>Tsuboi H, Hagiwara S, Asashima H, <i> et al.</i>: Comparison of performance of the 2016 ACR-EULAR classification criteria for primary Sjögren’s syndrome with other sets of criteria in Japanese patients. <i>Ann Rheum Dis.</i> 2017; <b>76</b>(12): 1980–5. <a target=xrefwindow id=d11211e1938 href="http://www.ncbi.nlm.nih.gov/pubmed/28330998">PubMed Abstract </a> | <a target=xrefwindow id=d11211e1941 href="https://doi.org/10.1136/annrheumdis-2016-210758">Publisher Full Text </a> | <a target=xrefwindow id=d11211e1945 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5705843">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727448421">F1000 Recommendation</a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d11211e1958 class=n-a></a>Shen L, Kapsogeorgou EK, Yu M, <i> et al.</i>: Evaluation of salivary gland protein 1 antibodies in patients with primary and secondary Sjogren’s syndrome. <i>Clin Immunol.</i> 2014; <b>155</b>(1): 42–6. <a target=xrefwindow id=d11211e1969 href="http://www.ncbi.nlm.nih.gov/pubmed/25178982">PubMed Abstract </a> | <a target=xrefwindow id=d11211e1972 href="https://doi.org/10.1016/j.clim.2014.08.009">Publisher Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d11211e1981 class=n-a></a>Shen L, Suresh L, Lindemann M, <i> et al.</i>: Novel autoantibodies in Sjogren’s syndrome. <i>Clin Immunol.</i> 2012; <b>145</b>(3): 251–5. <a target=xrefwindow id=d11211e1992 href="http://www.ncbi.nlm.nih.gov/pubmed/23123440">PubMed Abstract </a> | <a target=xrefwindow id=d11211e1995 href="https://doi.org/10.1016/j.clim.2012.09.013">Publisher Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732936360"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d11211e2004 class=n-a></a>Karakus S, Baer AN, Agrawal D, <i> et al.</i>: Utility of Novel Autoantibodies in the Diagnosis of Sjögrenʼs Syndrome Among Patients With Dry Eye. <i>Cornea.</i> 2018; <b>37</b>(4): 405–11. <a target=xrefwindow id=d11211e2015 href="http://www.ncbi.nlm.nih.gov/pubmed/29504954">PubMed Abstract </a> | <a target=xrefwindow id=d11211e2018 href="https://doi.org/10.1097/ICO.0000000000001471">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732936360">F1000 Recommendation</a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d11211e2031 class=n-a></a>Jousse-Joulin S, Milic V, Jonsson MV, <i> et al.</i>: Is salivary gland ultrasonography a useful tool in Sjögren’s syndrome? A systematic review. <i>Rheumatology (Oxford).</i> 2016; <b>55</b>(5): 789–800. <a target=xrefwindow id=d11211e2042 href="http://www.ncbi.nlm.nih.gov/pubmed/26667216">PubMed Abstract </a> | <a target=xrefwindow id=d11211e2045 href="https://doi.org/10.1093/rheumatology/kev385">Publisher Full Text </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d11211e2054 class=n-a></a>Chisholm DM, Mason DK: Labial salivary gland biopsy in Sjögren’s disease. <i>J Clin Pathol.</i> 1968; <b>21</b>(5): 656–60. <a target=xrefwindow id=d11211e2062 href="http://www.ncbi.nlm.nih.gov/pubmed/5697370">PubMed Abstract </a> | <a target=xrefwindow id=d11211e2065 href="https://doi.org/10.1136/jcp.21.5.656">Publisher Full Text </a> | <a target=xrefwindow id=d11211e2068 href="http://www.ncbi.nlm.nih.gov/pmc/articles/473887">Free Full Text </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d11211e2078 class=n-a></a>Tarpley TM Jr, Anderson LG, White CL: Minor salivary gland involvement in Sjögren’s syndrome. <i>Oral Surg Oral Med Oral Pathol.</i> 1974; <b>37</b>(1): 64–74. <a target=xrefwindow id=d11211e2086 href="http://www.ncbi.nlm.nih.gov/pubmed/4586901">PubMed Abstract </a> | <a target=xrefwindow id=d11211e2089 href="https://doi.org/10.1016/0030-4220(74)90160-1">Publisher Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d11211e2098 class=n-a></a>Greenspan JS, Daniels TE, Talal N, <i> et al.</i>: The histopathology of Sjögren’s syndrome in labial salivary gland biopsies. <i>Oral Surg Oral Med Oral Pathol.</i> 1974; <b>37</b>(2): 217–29. <a target=xrefwindow id=d11211e2109 href="http://www.ncbi.nlm.nih.gov/pubmed/4589360">PubMed Abstract </a> | <a target=xrefwindow id=d11211e2112 href="https://doi.org/10.1016/0030-4220(74)90417-4">Publisher Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d11211e2121 class=n-a></a>Daniels TE, Whitcher JP: Association of patterns of labial salivary gland inflammation with keratoconjunctivitis sicca. Analysis of 618 patients with suspected Sjögren’s syndrome. <i>Arthritis Rheum.</i> 1994; <b>37</b>(6): 869–77. <a target=xrefwindow id=d11211e2129 href="http://www.ncbi.nlm.nih.gov/pubmed/8003059">PubMed Abstract </a> | <a target=xrefwindow id=d11211e2132 href="https://doi.org/10.1002/art.1780370615">Publisher Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d11211e2141 class=n-a></a>Costa S, Quintin-Roué I, Lesourd A, <i> et al.</i>: Reliability of histopathological salivary gland biopsy assessment in Sjögren’s syndrome: a multicentre cohort study. <i>Rheumatology (Oxford).</i> 2015; <b>54</b>(6): 1056–64. <a target=xrefwindow id=d11211e2152 href="http://www.ncbi.nlm.nih.gov/pubmed/25433039">PubMed Abstract </a> | <a target=xrefwindow id=d11211e2155 href="https://doi.org/10.1093/rheumatology/keu453">Publisher Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727108079"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d11211e2164 class=n-a></a>Fisher BA, Jonsson R, Daniels T, <i> et al.</i>: Standardisation of labial salivary gland histopathology in clinical trials in primary Sjögren’s syndrome. <i>Ann Rheum Dis.</i> 2017; <b>76</b>(7): 1161–8. <a target=xrefwindow id=d11211e2175 href="http://www.ncbi.nlm.nih.gov/pubmed/27965259">PubMed Abstract </a> | <a target=xrefwindow id=d11211e2178 href="https://doi.org/10.1136/annrheumdis-2016-210448">Publisher Full Text </a> | <a target=xrefwindow id=d11211e2182 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5530351">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727108079">F1000 Recommendation</a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d11211e2195 class=n-a></a>Seror R, Ravaud P, Bowman SJ, <i> et al.</i>: EULAR Sjogren’s syndrome disease activity index: Development of a consensus systemic disease activity index for primary Sjogren’s syndrome. <i>Ann Rheum Dis.</i> 2010; <b>69</b>(6): 1103–9. <a target=xrefwindow id=d11211e2206 href="http://www.ncbi.nlm.nih.gov/pubmed/19561361">PubMed Abstract </a> | <a target=xrefwindow id=d11211e2209 href="https://doi.org/10.1136/ard.2009.110619">Publisher Full Text </a> | <a target=xrefwindow id=d11211e2213 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2937022">Free Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d11211e2223 class=n-a></a>Seror R, Theander E, Brun JG, <i> et al.</i>: Validation of EULAR primary Sjögren’s syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). <i>Ann Rheum Dis.</i> 2015; <b>74</b>(5): 859–66. <a target=xrefwindow id=d11211e2234 href="http://www.ncbi.nlm.nih.gov/pubmed/24442883">PubMed Abstract </a> | <a target=xrefwindow id=d11211e2237 href="https://doi.org/10.1136/annrheumdis-2013-204615">Publisher Full Text </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d11211e2246 class=n-a></a>Nishikawa A, Suzuki K, Kassai Y, <i> et al.</i>: Identification of definitive serum biomarkers associated with disease activity in primary Sjögren’s syndrome. <i>Arthritis Res Ther.</i> 2016; <b>18</b>(1): 106. <a target=xrefwindow id=d11211e2257 href="http://www.ncbi.nlm.nih.gov/pubmed/27180164">PubMed Abstract </a> | <a target=xrefwindow id=d11211e2260 href="https://doi.org/10.1186/s13075-016-1006-1">Publisher Full Text </a> | <a target=xrefwindow id=d11211e2264 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4868006">Free Full Text </a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/731260330"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d11211e2273 class=n-a></a>Kanne AM, Jülich M, Mahmutovic A, <i> et al.</i>: Association of High Mobility Group Box Chromosomal Protein 1 and Receptor for Advanced Glycation End Products Serum Concentrations With Extraglandular Involvement and Disease Activity in Sjögren’s Syndrome. <i>Arthritis Care Res (Hoboken).</i> 2018; <b>70</b>(6): 944–8. <a target=xrefwindow id=d11211e2284 href="http://www.ncbi.nlm.nih.gov/pubmed/28941024">PubMed Abstract </a> | <a target=xrefwindow id=d11211e2287 href="https://doi.org/10.1002/acr.23420">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/731260330">F1000 Recommendation</a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732962337"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d11211e2300 class=n-a></a>James K, Chipeta C, Parker A, <i> et al.</i>: B-cell activity markers are associated with different disease activity domains in primary Sjögren’s syndrome. <i>Rheumatology (Oxford).</i> 2018; <b>57</b>: 1222–7. <a target=xrefwindow id=d11211e2311 href="http://www.ncbi.nlm.nih.gov/pubmed/29608774">PubMed Abstract </a> | <a target=xrefwindow id=d11211e2314 href="https://doi.org/10.1093/rheumatology/key063">Publisher Full Text </a> | <a target=xrefwindow id=d11211e2318 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6014143">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732962337">F1000 Recommendation</a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/736461007"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d11211e2331 class=n-a></a>Martire MV, Santiago ML, Cazenave T, <i> et al.</i>: Latest Advances in Ultrasound Assessment of Salivary Glands in Sjögren Syndrome. <i>J Clin Rheumatol.</i> 2018; <b>24</b>(4): 218–23. <a target=xrefwindow id=d11211e2342 href="http://www.ncbi.nlm.nih.gov/pubmed/29239938">PubMed Abstract </a> | <a target=xrefwindow id=d11211e2345 href="https://doi.org/10.1097/RHU.0000000000000625">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/736461007">F1000 Recommendation</a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d11211e2358 class=n-a></a>Niemelä RK, Takalo R, Pääkkö E, <i> et al.</i>: Ultrasonography of salivary glands in primary Sjogren’s syndrome. A comparison with magnetic resonance imaging and magnetic resonance sialography of parotid glands. <i>Rheumatology (Oxford).</i> 2004; <b>43</b>(7): 875–9. <a target=xrefwindow id=d11211e2369 href="http://www.ncbi.nlm.nih.gov/pubmed/15113992">PubMed Abstract </a> | <a target=xrefwindow id=d11211e2372 href="https://doi.org/10.1093/rheumatology/keh187">Publisher Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d11211e2382 class=n-a></a>Jousse-Joulin S, Devauchelle-Pensec V, Cornec D, <i> et al.</i>: Brief Report: Ultrasonographic Assessment of Salivary Gland Response to Rituximab in Primary Sjögren’s Syndrome. <i>Arthritis Rheumatol.</i> 2015; <b>67</b>(6): 1623–8. <a target=xrefwindow id=d11211e2393 href="http://www.ncbi.nlm.nih.gov/pubmed/25708147">PubMed Abstract </a> | <a target=xrefwindow id=d11211e2396 href="https://doi.org/10.1002/art.39088">Publisher Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732359993"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d11211e2405 class=n-a></a>Fisher BA, Everett CC, Rout J, <i> et al.</i>: Effect of rituximab on a salivary gland ultrasound score in primary Sjögren’s syndrome: results of the TRACTISS randomised double-blind multicentre substudy. <i>Ann Rheum Dis.</i> 2018; <b>77</b>(3): 412–6. <a target=xrefwindow id=d11211e2416 href="http://www.ncbi.nlm.nih.gov/pubmed/29275334">PubMed Abstract </a> | <a target=xrefwindow id=d11211e2419 href="https://doi.org/10.1136/annrheumdis-2017-212268">Publisher Full Text </a> | <a target=xrefwindow id=d11211e2423 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5867400">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732359993">F1000 Recommendation</a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d11211e2436 class=n-a></a>Holdgate N, St Clair EW: Recent advances in primary Sjogren's syndrome [version 1; peer review: 3 approved]. <i>F1000Res.</i> 2016; <b>5</b>: pii: F1000 Faculty Rev-1412. <a target=xrefwindow id=d11211e2444 href="http://www.ncbi.nlm.nih.gov/pubmed/27347394">PubMed Abstract </a> | <a target=xrefwindow id=d11211e2447 href="https://doi.org/10.12688/f1000research.8352.1">Publisher Full Text </a> | <a target=xrefwindow id=d11211e2450 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4916986">Free Full Text </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d11211e2459 class=n-a></a>Mariette X, Seror R, Quartuccio L, <i> et al.</i>: Efficacy and safety of belimumab in primary Sjögren’s syndrome: results of the BELISS open-label phase II study. <i>Ann Rheum Dis.</i> 2015; <b>74</b>(3): 526–31. <a target=xrefwindow id=d11211e2470 href="http://www.ncbi.nlm.nih.gov/pubmed/24347569">PubMed Abstract </a> | <a target=xrefwindow id=d11211e2473 href="https://doi.org/10.1136/annrheumdis-2013-203991">Publisher Full Text </a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d11211e2482 class=n-a></a>De Vita S, Quartuccio L, Seror R, <i> et al.</i>: Efficacy and safety of belimumab given for 12 months in primary Sjögren’s syndrome: the BELISS open-label phase II study. <i>Rheumatology (Oxford).</i> 2015; <b>54</b>(12): 2249–56. <a target=xrefwindow id=d11211e2493 href="http://www.ncbi.nlm.nih.gov/pubmed/26242856">PubMed Abstract </a> | <a target=xrefwindow id=d11211e2496 href="https://doi.org/10.1093/rheumatology/kev257">Publisher Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d11211e2505 class=n-a></a>Dörner T, Posch M, Wagner F, <i> et al.</i>: THU0313 Double-Blind, Randomized Study of VAY736 Single Dose Treatment in Patients with Primary Sjögren’s Syndrome (PSS). <i>Ann Rheum Dis.</i> 2016; <b>75</b>(Suppl 2): 300.3–301. <a target=xrefwindow id=d11211e2516 href="https://doi.org/10.1136/annrheumdis-2016-eular.5840">Publisher Full Text </a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735506719"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d11211e2526 class=n-a></a>Felten R, Scher F, Sibilia J, <i> et al.</i>: The pipeline of targeted therapies under clinical development for primary Sjögren’s syndrome: A systematic review of trials. <i>Autoimmun Rev.</i> 2019; <b>18</b>(6): 576–82. <a target=xrefwindow id=d11211e2537 href="http://www.ncbi.nlm.nih.gov/pubmed/30959220">PubMed Abstract </a> | <a target=xrefwindow id=d11211e2540 href="https://doi.org/10.1016/j.autrev.2018.12.008">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735506719">F1000 Recommendation</a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d11211e2553 class=n-a></a>Cornec D, Costa S, Devauchelle-Pensec V, <i> et al.</i>: Blood and salivary-gland BAFF-driven B-cell hyperactivity is associated to rituximab inefficacy in primary Sjögren’s syndrome. <i>J Autoimmun.</i> 2016; <b>67</b>: 102–10. <a target=xrefwindow id=d11211e2564 href="http://www.ncbi.nlm.nih.gov/pubmed/26688003">PubMed Abstract </a> | <a target=xrefwindow id=d11211e2567 href="https://doi.org/10.1016/j.jaut.2015.11.002">Publisher Full Text </a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d11211e2576 class=n-a></a>Pers JO, Devauchelle V, Daridon C, <i> et al.</i>: BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome. <i>Arthritis Rheum.</i> 2007; <b>56</b>(5): 1464–77. <a target=xrefwindow id=d11211e2587 href="http://www.ncbi.nlm.nih.gov/pubmed/17469105">PubMed Abstract </a> | <a target=xrefwindow id=d11211e2590 href="https://doi.org/10.1002/art.22603">Publisher Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735234592"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d11211e2599 class=n-a></a>Dörner T, Posch MG, Li Y, <i> et al.</i>: Treatment of primary Sjögren’s syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity. <i>Ann Rheum Dis.</i> 2019; <b>78</b>(5): 641–7. <a target=xrefwindow id=d11211e2610 href="http://www.ncbi.nlm.nih.gov/pubmed/30826774">PubMed Abstract </a> | <a target=xrefwindow id=d11211e2613 href="https://doi.org/10.1136/annrheumdis-2018-214720">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735234592">F1000 Recommendation</a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734495991"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d11211e2626 class=n-a></a>Nayar S, Campos J, Smith CG, <i> et al.</i>: Phosphatidylinositol 3-kinase delta pathway: a novel therapeutic target for Sjögren’s syndrome. <i>Ann Rheum Dis.</i> 2019; <b>78</b>(2): 249–60. <a target=xrefwindow id=d11211e2637 href="http://www.ncbi.nlm.nih.gov/pubmed/30472652">PubMed Abstract </a> | <a target=xrefwindow id=d11211e2640 href="https://doi.org/10.1136/annrheumdis-2017-212619">Publisher Full Text </a> | <a target=xrefwindow id=d11211e2644 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6352416">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734495991">F1000 Recommendation</a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d11211e2657 class=n-a></a>Dörner T, Zeher M, Laessing U, <i> et al.</i>: OP0250 A randomised, double-blind study to assess the safety, tolerability and preliminary efficacy of leniolisib (CDZ173) in patients with primary sjÖgren’s syndrome. <i>Ann Rheum Dis.</i> 2018; <b>77</b>(Suppl 2): 174.1–174. <a target=xrefwindow id=d11211e2668 href="https://doi.org/10.1136/annrheumdis-2018-eular.3111">Publisher Full Text </a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735105835"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d11211e2678 class=n-a></a>Bodewes ILA, Björk A, Versnel MA, <i> et al.</i>: Innate immunity and interferons in the pathogenesis of Sjögren’s syndrome. <i>Rheumatology (Oxford).</i> 2019; pii: key360. <a target=xrefwindow id=d11211e2686 href="http://www.ncbi.nlm.nih.gov/pubmed/30770713">PubMed Abstract </a> | <a target=xrefwindow id=d11211e2689 href="https://doi.org/10.1093/rheumatology/key360">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735105835">F1000 Recommendation</a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d11211e2702 class=n-a></a>Seror R, Nocturne G, Lazure T, <i> et al.</i>: Low numbers of blood and salivary natural killer cells are associated with a better response to belimumab in primary Sjögren’s syndrome: results of the BELISS study. <i>Arthritis Res Ther.</i> 2015; <b>17</b>: 241. <a target=xrefwindow id=d11211e2713 href="http://www.ncbi.nlm.nih.gov/pubmed/26336930">PubMed Abstract </a> | <a target=xrefwindow id=d11211e2716 href="https://doi.org/10.1186/s13075-015-0750-y">Publisher Full Text </a> | <a target=xrefwindow id=d11211e2720 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4559969">Free Full Text </a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a name=d11211e2729 class=n-a></a>James J, Guthridge J, Chen H, <i> et al.</i>: Molecular Features Define Unique Sjogren’s Syndrome Patient Subsets [abstract]. <i>Arthritis Rheumatol.</i> 2017; <b>69</b>(Supplement 10). <a target=xrefwindow id=d11211e2740 href="https://acrabstracts.org/abstract/molecular-features-define-unique-sjogrens-syndrome-patient-subsets/">Reference Source</a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733491023"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d11211e2749 class=n-a></a>Lee J, Lee J, Kwok SK, <i> et al.</i>: JAK-1 Inhibition Suppresses Interferon-Induced BAFF Production in Human Salivary Gland: Potential Therapeutic Strategy for Primary Sjögren’s Syndrome. <i>Arthritis Rheumatol.</i> 2018; <b>70</b>(12): 2057–66. <a target=xrefwindow id=d11211e2760 href="http://www.ncbi.nlm.nih.gov/pubmed/29927095">PubMed Abstract </a> | <a target=xrefwindow id=d11211e2763 href="https://doi.org/10.1002/art.40589">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733491023">F1000 Recommendation</a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d11211e2776 class=n-a></a>Dimitriou ID, Kapsogeorgou EK, Moutsopoulos HM, <i> et al.</i>: CD40 on salivary gland epithelial cells: High constitutive expression by cultured cells from Sjögren’s syndrome patients indicating their intrinsic activation. <i>Clin Exp Immunol.</i> 2002; <b>127</b>(2): 386–92. <a target=xrefwindow id=d11211e2787 href="http://www.ncbi.nlm.nih.gov/pubmed/11876766">PubMed Abstract </a> | <a target=xrefwindow id=d11211e2790 href="https://doi.org/10.1046/j.1365-2249.2002.01752.x">Publisher Full Text </a> | <a target=xrefwindow id=d11211e2794 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1906327">Free Full Text </a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735386651"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d11211e2803 class=n-a></a>Wieczorek G, Bigaud M, Pfister S, <i> et al.</i>: Blockade of CD40-CD154 pathway interactions suppresses ectopic lymphoid structures and inhibits pathology in the NOD/ShiLtJ mouse model of Sjögren's syndrome. <i>Ann Rheum Dis.</i> 2019; <b>78</b>(7): 974–8. <a target=xrefwindow id=d11211e2814 href="http://www.ncbi.nlm.nih.gov/pubmed/30902822">PubMed Abstract </a> | <a target=xrefwindow id=d11211e2817 href="https://doi.org/10.1136/annrheumdis-2018-213929">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735386651">F1000 Recommendation</a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735638311"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d11211e2831 class=n-a></a>Fox RI, Fox CM, Gottenberg JE, <i> et al.</i>: Treatment of Sjögren’s syndrome: current therapy and future directions. <i>Rheumatology (Oxford).</i> 2019; <b>69</b>: 517, pii: kez142. <a target=xrefwindow id=d11211e2842 href="http://www.ncbi.nlm.nih.gov/pubmed/31034046">PubMed Abstract </a> | <a target=xrefwindow id=d11211e2845 href="https://doi.org/10.1093/rheumatology/kez142">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735638311">F1000 Recommendation</a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 29 Aug 2019</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/8-1532/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/8-1532/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Department of Medicine, Division of Rheumatology and Immunology, School of Medicine, Duke University, 40 Duke Medicine Circle, Durham, NC, 27110, USA<br/> <p> <div class=margin-bottom> David L. Leverenz <br/> <span>Roles: </span> Conceptualization, Data Curation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> E. William St. Clair <br/> <span>Roles: </span> Conceptualization, Data Curation, Project Administration, Supervision, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/8-1532/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 29 Aug 2019, 8:1532 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.19842.1">https://doi.org/10.12688/f1000research.19842.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2019 Leverenz DL and St. Clair EW. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=21770 data-id=19842 data-downloads="" data-views="" data-scholar="10.12688/f1000research.19842.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/8-1532/v1/pdf?article_uuid=9c7745fc-6f25-43ef-828b-474d9001c418" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.19842.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Leverenz DL and St. Clair EW. Recent advances in the search for a targeted immunomodulatory therapy for primary Sj&ouml;gren’s syndrome [version 1; peer review: 2 approved] <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):1532 (<a href="https://doi.org/10.12688/f1000research.19842.1" target=_blank>https://doi.org/10.12688/f1000research.19842.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=19842 id=mobile-track-article-signin-19842 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/19842?target=/articles/8-1532/v1"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=21770 /> <input name=articleId type=hidden value=19842 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Alain Saraux</strong>, Rheumatology Unit, Centre National de Référence des Maladies Auto-Immunes Rares (CERAINO), LBAI, U1227, Univ Brest, France </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> Dr. Saraux reports grants, personal fees or non-financial support from Abbvie, Bristol Myers Squibb, Lilly, MSD, Novartis, Pfizer, Roche-Chugai, UCB. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Robert Fox</strong>, Scripps Memorial Hospital and Research Foundation, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 29 Aug 2019</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/8-1532/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/8-1532/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=55980-52887></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=55979-52888></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/8-1532/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>29 Aug 19</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Alain Saraux</strong>, Rheumatology Unit, Centre National de Référence des Maladies Auto-Immunes Rares (CERAINO), LBAI, U1227, Univ Brest, France </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> Dr. Saraux reports grants, personal fees or non-financial support from Abbvie, Bristol Myers Squibb, Lilly, MSD, Novartis, Pfizer, Roche-Chugai, UCB. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Robert Fox</strong>, Scripps Memorial Hospital and Research Foundation, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/8-1532/v1&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/8-1532/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Recent advances in the search for a targeted...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/8-1532/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/8-1532/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/8-1532/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Leverenz DL and St. Clair EW');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/8-1532/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/8-1532",
            templates : {
                twitter : "Recent advances in the search for a targeted immunomodulatory.... Leverenz DL and St. Clair EW, published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/8-1532/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Recent advances in the search for a targeted immunomodulatory therapy for primary Sj\u00F6gren\u2019s syndrome", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Recent advances in the search for a targeted immunomodulatory therapy for primary Sj\u00F6gren\u2019s syndrome", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/19842/21770")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "21770");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "52887": 0,
                           "52888": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "c1e6da51-5206-4efb-b976-c0f1befa4756";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-1532.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-1532.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-1532.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/8-1532.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/8-1532.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>